Our data suggest that Ron receptor tyrosine kinase function in prostate tumorigenesis is dependent on ligand-mediated activation with these findings implicating for the first time the Ron ligand, HGFL, as a novel therapeutic target in prostate cancer. The gene discussed is MST1R; the disease is prostate carcinoma.